Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00
Provider: Thomson Reuters StreetEvents
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Almirall SA’s Partner, Kyorin Pharmaceutical Co., Announces Positive Trial Results On Efficacy Of Aclidinium


Monday, 18 Mar 2013 03:35am EDT 

Almirall SA announced that its Partner, Kyorin Pharmaceutical Co., has successfully completed a confirmatory clinical trial of efficacy of aclidinium in Japanese population. The study included Japanese patients suffering from COPD (chronic obstructive pulmonary disease). Shortly a consultation with the Japanese Regulatory Agency (PMDA) will be held to determine the next steps. 

Company Quote

10.7
-0.1 -0.93%
17 Apr 2014